Company Profile
D&D Pharmatech provides the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase.
Its portfolio also includes injectable peptides, including DD01 for MASH indications, NLY12 and DD15 for obesity indications, and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases.
The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications. Its portfolio also includes NLY02, an oral small molecule for PD and AD indications, and P4M01 for anti-microbial peptide indications.
Additionally, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. Founded in 2014, the company is based in Seongnam-si, South Korea.